AZN Astrazeneca PLC Common Stock

34.08
+0.13  (0%)
Previous Close 33.95
Open 33.91
Price To book 6.62
Market Cap 86.29B
Shares 2,532,000,000
Volume 3,979,157
Short Ratio 6.76
Av. Daily Volume 4,366,860

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data due 2H 2017.
Tralokinumab (STRATOS2)
Severe, uncontrolled asthma
Phase 3 trial commenced 1Q 2017.
Dapa-HF
Heart failure
Phase 3 data due 2018.
Benralizumab
COPD
Phase 3 data due 2019.
Farxiga - DECLARE
Cardiovascular Outcomes
Approval announced March 31, 2017.
Tagrisso
Epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC)
Phase 3 data due 2020.
Durvalumab (ADJUVANT)
Adjuvant Non-small cell lung cancer (NSCLC)
Phase 3 data due 2019.
AZD3293
Early Alzheimer's disease
Phase 3 trial did not meet primary endpoint - May 10, 2017.
Tralokinumab (STRATOS1)
Severe, uncontrolled asthma
Phase 3 data due 2018.
Selumetinib - ASTRA
Thyroid cancer
Phase 3 data due 2H 2017.
Tagrisso
First-line lung cancer
Phase 3 data due 2018.
Roxadustat - ANDES
Anaemia
Phase 3 data due 2018.
PT010
Chronic obstructive pulmonary disease (COPD)
Phase 3 data due 2H 2017.
Moxetumomab
Cancer - leukaemia
Phase 3 data due 2H 2017.
Lynparza
First-line ovarian cancer
Data presented March 14, 2017 showed significant PFS benefit. PDUFA date under priority review 3Q 2017. Estimate September 28, 2017 assuming 6-month review.
Lynparza - SOLO 2
Second-line ovarian cancer
Phase 3 data released February 17, 2016 - primary endpoint met. Late breaker at ASCO June 4, 2017. Abstract LBA4.
Lynparza
Breast cancer
NDA filed 4Q 2016.
Faslodex
Breast cancer
Phase 3 PFS data mid-2017.
Durvalumab +/- tremelimumab (MYSTIC)
Lung cancer
Phase 3 data due 2018.
Durvalumab +/- tremelimumab (NEPTUNE)
Lung cancer
Phase 3 data due 2H 2017.
Durvalumab +/- tremelimumab (KESTREL)
Head & neck cancer
Phase 3 data due 2018.
Durvalumab +/- tremelimumab (DANUBE)
Bladder cancer
Phase 3 data due 2018.
Durvalumab +/- tremelimumab (EAGLE)
Head & neck cancer
Phase 3 data 4Q 2017.
Durvalumab +/- tremelimumab (ARCTIC)
Lung cancer
Phase 3 interim analysis released May 12, 2017 - PFS primary endpoint already met. OS endpoint to be assessed.
Durvalumab (PACIFIC)
Lung cancer
Phase 3 Cardiovascular Outcome trial data due 3Q 2017.
Bydureon
Type 2 Diabetes
Phase 3 data due 1Q 2018.
Brilinta (THEMIS)
Type 2 Diabetes
Phase 3 data due 2018.
Anifrolumab
Lupus
Phase 2 data 2Q or mid 2017.
Acalabrutinib - ACE-LY-004
Relapsed or Refractory Mantle Cell Lymphoma
BLA acceptance announced December 9, 2017. PDUFA under priority review. Approval announced May 1, 2017.
Urothelial carcinoma - Bladder cancer
Bladder cancer
Second CRL issued March 17, 2017.
ZS-9
Hyperkalaemia
Approval announced February 28, 2017.
Saxagliptin and dapagliflozin
Type-2 diabetes
Guided in November for a regulatory filing by the end of 2016.
Benralizumab
Severe, uncontrolled asthma

Latest News

  1. Novo Nordisk Diabetes Lead Unscathed Following AstraZeneca Trial
  2. New Research Reports for Oracle, Chubb, AstraZeneca & Others
  3. AstraZeneca Sells Marketing Rights to Seloken in Europe
  4. AstraZeneca PLC (AZN): Strong Industry, Solid Earnings Estimate Revisions
  5. BYDUREON EXSCEL Trial Meets Primary Safety Objective in Type-2 Diabetes Patients at Wide Range of Cardiovascular Risk
  6. AstraZeneca Shares Rise as Investors Shrug Off Mixed Diabetes Results
  7. Astrazeneca (AZN) Gets Positive CHMP Opinion for Brodalumab
  8. Phase III ZONDA Trial for benralizumab Shows Ability to Reduce Oral Steroid Use in Severe Asthma Patients
  9. Severe asthma drug shows AstraZeneca promise beyond cancer
  10. [$$] AstraZeneca sells Seloken European rights for $300m
  11. AstraZeneca sells ageing beta-blocker to Recordati for $300 mln
  12. Build Your Investing Watch List With Stock Ratings, Buy Zones, Earnings
  13. Big Pharma Stock Astrazeneca Gets Relative Strength Upgrade
  14. Vertex Pharmaceuticals' Shares Pop in Afterhours Trading After FDA Approval while AstraZeneca Sinks on Clovis Upgrade
  15. Did AstraZeneca Rival Just Launch A Potential Blockbuster Drug?
  16. Eli Lilly: Worries Ahead In Patent Fight
  17. [$$] Big pharma hopes rule change will ease China sales pain
  18. AstraZeneca Has Opportunity In Lung Cancer Treatment Vs. Dow's Merck
  19. AstraZeneca Imfinzi Positive in Phase III Lung Cancer Study
  20. AstraZeneca (AZN) Shows Strength: Stock Moves 9.2% Higher